IndustryCompany release

Cerus reports 10% Q3 product revenue growth and positive Phase 3 RedeS red cell topline

🇺🇸 Cerus Corp (CERS) · Mon 02 Nov 2026

The US pathogen-reduction specialist posted $57.7 million in third-quarter product revenue and announced positive topline Phase 3 results for its INTERCEPT system for red blood cells.

Cerus Corporation reported third-quarter 2026 results on 2 November, with total revenue of $64.0 million. Product revenue reached $57.7 million, which the company put at a 10% increase.

According to the company, growth was supported by sales of INTERCEPT Fibrinogen Complex, ongoing demand for platelet products, and sales of the INT200 illuminator in EMEA.

Cerus also announced positive topline results from RedeS, its Phase 3 trial of the INTERCEPT Blood System for red blood cells. The summary available to VigiEye gives no detail on endpoints, patient numbers or the regulatory path, so the clinical findings cannot yet be assessed.

The company reiterated its full-year 2026 product revenue guidance of $229 million to $231 million.

What it means for your team

  • Regulatory teams tracking pathogen-reduction technologies should watch for detailed RedeS data and any filing plans, which have not yet been disclosed in the information available.
  • Blood establishments and transfusion services in EMEA may see continued uptake of INT200 illuminators, as sales in the region contributed to the quarter's growth.
  • Market-access and procurement teams can note that the full-year product revenue guidance of $229-231 million was unchanged.

Company's press release (SEC filing): Cerus Corp ↗

Article written by VigiEye from the official source (Cerus Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →